Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
where is the link? $LJPC
$NTN (0.37) volume exploding from last 3 days, seems like ready to run
IMUC (1.05) - ImmunoCellular Therapeutics Prices Underwritten Offering Of 9.49 Mln Units
(RTTNews) - ImmunoCellular Therapeutics Ltd. (IMUC.OB: News ) said it priced an underwritten offering of 9.49 million units, each unit consisting of one common share and a warrant to buy one half of a common share, at a public offering price of $1.10 per unit. The company expects to receive net proceeds of about $9.4 million, after deducting the underwriting discount and estimated offering expenses.
http://www.rttnews.com/1795022/immunocellular-therapeutics-prices-underwritten-offering-of-9-49-mln-units.aspx?type=qf
Hepatitis C Drug Developers Shares Soar After Bristol Deal
Not all analysts were buying into the rally. Brean Murray Carret & Co. analyst Brian Skorney wrote in a note that Idenix's effort in the space "will ultimately yield results that do not match what we have become accustomed to" from others. Skorney affirmed his sell rating and $3 price target on the stock.
http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=20120109-01038&title=hepatitis-c-drug-developers-shares-soar-after-bristol-deal
web link?
web link?
NGSX (1.07) - PDUFA - March 7, 2012
NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
http://ngsx.client.shareholder.com/releasedetail.cfm?ReleaseID=623683
NGSX (1.07) - PDUFA - March 7, 2012
NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
http://ngsx.client.shareholder.com/releasedetail.cfm?ReleaseID=623683
NGSX (1.15) - (NGSX) NeurogesX poised for favorable partnership deal, says Roth Capital
After NeurogesX reported data for its NGX-1998 topical capsaicin candidate that Roth Capital views as impressive, the firm thinks the company is poised to obtain a favorable partnership deal with a larger drug company. The firm maintains a Buy rating on the stock. theflyonthewall.com
NGSX (1.10) - NeurogesX - Of Pain And Gain
http://www.rttnews.com/Content/BiotechStory.aspx?Id=1749266&Category=PendingClinical
NGSX (1.20) is down 20%, is this news the reason?
NeurogesX Announces Resignation of EVP of Research and Development and Chief Medical Officer Jeffrey K Tobias, MD
http://www.marketwatch.com/story/neurogesx-announces-resignation-of-evp-of-research-and-development-and-chief-medical-officer-jeffrey-k-tobias-md-2011-09-27
How and where do you check that volume has started picking up?
Do you compare each day's volume? e.g. at http://www.otcmarkets.com/stock/NGSX/chart
Are you holding NGSX?
NGSX (1.62) NeurogesX Submits Supplemental New Drug Application for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
http://ngsx.client.shareholder.com/releasedetail.cfm?ReleaseID=604008
what's your opinion about NGSX?
NGSX (1.61) - NeurogesX Submits Supplemental New Drug Application for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
http://ngsx.client.shareholder.com/releasedetail.cfm?ReleaseID=604008
GENT - Gentium Shares Down 35% After Withdrawal Of NDA Submission For Defibrotide
http://www.rttnews.com/ArticleView.aspx?ID=1694922
BIEL - is anyone holding BIEL in Zecco trading account?
Zecco told me that one has to pay between $200-700 + trading commissions in order to sell/buy this stock. The exact amount ($200-700) will be known in 1-2 months time.
Is anybody facing similar issue when trying to buy/sell BIEL with Zecco or any other company?
PATH - hit low of the year $4.46, what's wrong with this company?
They have also announced
NuPathe Announces Common Stock Purchase Agreement for up to $30 Million
http://www.marketwatch.com/story/nupathe-announces-common-stock-purchase-agreement-for-up-to-30-million-2011-08-02?reflink=MW_news_stmp
NGSX - Wedbush has $9.50 target for it, this is nice run up candidate for this quarter.
recent dilution, yesterday's insider buys and sNDA filling is due sometime soon
IGXT is down to 0.77, it's finding hard to move up
IGXT is down to 0.77, it's finding hard to move up
NGSX announced $20 mln private placement but they had filled S-3 for $75 mln. Does this means they are going to sell more?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=53023099
NGSX has earning announcement on August 4, 2011, Do you think its going to fall? During the last earning announcements it had fallen.
TLON - Talon Therapeutics Submits New Drug Application for Marqibo(R)
http://finance.yahoo.com/news/Talon-Therapeutics-Submits-pz-3091391821.html?x=0&.v=1
THLD (1.79) - is there any near term catalyst (pending/ coming) for this one?
Is today's jump because of some technical indicator or some news is out?
Sorry I saw your earlier posting, thanks
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64152194
NGSX - What's your opinion about NGSX?
why is it going down everyday?
Is it a buy? What's your thoughts about this company?
I think management is saying they plans to buy back the debt at discounted price. After management will buy back company will be debt free.
Is this good or bad? seems to be good but existing sharholders will suffer. Any thoughts
If NEOP has to sell securities after the Phase-3 then why they have filed S-3 now why not after positive phase-3 results?
Is there any reason for filing this document before phase-3 results not after?
Any idea what is this mean?
S-1 Filling - This is an initial public offering of Insys Therapeutics, Inc. We are offering shares of common stock. We currently estimate that the
initial public offering price of our common stock will be between $ and $ per share.
We have filed an application for our common stock to be listed on the Nasdaq Global Market under the symbol “INRX.”
http://secfilings.com/searchresultswide.aspx?TabIndex=2&FilingID=7826829&type=convpdf&companyid=851566&ppu=%2fDefault.aspx%3fauth%3d1%26amp%3bticker%3dNEOL
When are they (ALQA) planning to submit 505(b)(2) or ANDA?
How do check how many shares are available?
"Not many shares available under 4$"
What's your thought about XNPT?
IPCI - I have noticed whenever BioMedReports write about some company stock price go up and then immediately after that stock offering news comes.
Intellipharmaceutics Announces US$12,000,000 Financing
http://www.thestreet.com/story/10981476/1/intellipharmaceutics-announces-us12000000-financing.html
ANX (2.29) What's your thoughts about ANX? It has PDUFA date of Sep 1, 2011 for the review of the Exelbine (ANX-530).
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=ANX×tamp=20110119130200
VICL (2.07) Vical Incorporated, What's your thought about VICL?
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
http://clinicaltrials.gov/ct2/show/NCT00395070?term=NCT00395070&rank=1
Estimated Enrollment: 375
Study Start Date: October 2006
Estimated Study Completion Date: August 2011
Estimated Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
The United States Department of Naval Medical Research Center (NMRC)
intends to make a sole source award to Vical Inc. for the production of novel DNA vaccines and participation with the Transformational Medical Therapeutics Program (TMT) of the Defense Threat Reduction Agency (DTRA) during upcoming excercises in FY2011 by providing proprietary products and processes.
https://www.fbo.gov/index?s=opportunity&mode=form&id=5dc3781a7a4596adf8e083f6bca665fe&tab=core&_cview=0
@2.25 public offering
Vical Incorporated Prices Public Offering of Common Stock
http://www.globenewswire.com/newsroom/news.html?d=202283